Faes Farma, S.a. · BME:FAE
Faes Farma — 9M 2024 Earnings Presentation
18 slides from Faes Farma's earnings presentation, October 2024
Slide 1: Business update 9M 2024
Business update 9M 2024 October 2024
Slide 2: Index
Index 1// 2// 3// Overview Business Results 9M 2024 update 9M and outlook 2024
Slide 3: Overview 9M 2024
Overview 9M 2024 oF FAES FARMA
Slide 4: Highlights
Overview 9M 2024 Highlights The positive trend from the start of the year continues in Q3, with revenue growth driven mainly by the BUSINESS good performance of Pharma in Spain and in international markets. Positive cash generation after the dividend payment in July and following the near completion
Slide 5: Key figures
Overview 9M 2024 Key figures Total 392,9 M€ 109,5 M€ EBITDA* Income +8,5% +7,6% Income 155,7 M€ EBIT** 94,4 M€ top3 +9,3% +7,8% molecules Total 79,8M€ 221,9 M€ international NET +7,7% +9% income profit*** Rounded data *Operating profit before depreciation, amortisation and impairment ** Operating pr
Slide 6: Business update 9M 2024
2// Business update 9M 2024 6
Slide 7: Pharma portfolio continues to grow at a solid pace
Business uptdate 9M 2024 Pharma portfolio continues to grow at a solid pace Total income by portfolio line M€ Animal and health nutrition Pharma top 3 molecules 9M 2024 9M 2023 % 10% 40% Pharma 353,8 322,6 10% Pharma top 3 molecules 155,7 142,4 9% Rest of Pharma 198,2 180,2 10% Animal Nutrition and
Slide 8: Evolution top 3 molecules
Business evolution 9M 2024 Evolution top 3 molecules Positive performance in international markets (+9%) . Growth in Spain (+3%) despite price reductions by the BILASTINE 101,5 M€ authorities (at the end of 2023). +6% Good performance in Spain (+7%), although sales growth is mainly driven by the per
Slide 9: Total income by business area and geography
Business evolution 9M 2024 Overall positive developments in Pharma geographies Total income by business area M€ Animal Nutrition Pharma 9M 2024 9M 2023 % and Health Spain Pharma Pharma 353,8 322,6 10% 10% 34% Licenses Pharma Spain 132,7 121,6 9% 22% Pharma International (without licenses) 136,0 120,
Slide 10: Pharma Spain. Continued positive trend in the different channels
Business evolution 9M 2024 Pharma Spain. Continued positive trend in the different channels INCOME PHARMA SPAIN Highlights 9M 2024 9M 2024 9M 2023 %var PRESCRIPTION Spain Pharma 132,7 121,6 9% • The positive trend from S1 continues. • The respiratory franchise continued to Prescription 85,0 77,3 10%
Slide 11: Pharma International (without licenses). Continued good performance
Business evolution 9M 2024 Pharma Internacional (without licenses). Continued good performance especially in the new Middle East project INCOME INTERNATIONAL (without licenses) 9M 2024 9M 2023 %var Highlights 9M 2024 M€ International (withour licenses) 136,0 120,3 13% Subsidiaries LATAM 70,9 64,3 10
Slide 12: Licencias. Growth trend in line with expectations
Business evolution 9M 2024 Licencias. Growth trend in line with expectations Highlights 9M 2024 INCOME LICENSES BILASTINE M€ 9M 2024 9M 2023 %var • Bilastine sales performed better than expected. Asia Pacific (+26%) and Canada (+29%, despite patent expiry) accelerated Licenses 85,1 80,7 5% growth, w
Slide 13: Farm Faes. Sector context steadily improves
Business evolution 9M 2024 Farm Faes. Sector context steadily improves Highlights 9M 2024 INCOME FARM FAES M€ 9M 2024 9M 2023 %var • The decline in income continues to slow progressively, although the pig sector continues Animal nutrition and health 39,1 39,4 -1% to be affected by emerging diseases.
Slide 14: Results and outlook
3// Results and outlook 14
Slide 15: High single-digit growth of all magnitudes
Results and outlook High single-digit growth of all magnitudes Thousand € 9M 2024 9M 2023 %change Ordinary income (sales) 379.535 343.284 10,6% Highlights 9M 2024 Other operating income 13.381 18.688 -28,4% Tota Income 392.916 361.972 8,5% • Sales growth exceeding the percentage target for Cost of s
Slide 16: We expect to end the year in the high range of the 2024 forecast
Results and Outlook 2024 We expect to end the year in the high range of the 2024 forecast range in both revenues and EBITDA. Guidance 2024 Impacts + 2024 Impacts - 2024 Other issues with an impact on the P&L • Double digit growth in • Increase in personnel 2024 LATAM & OMA costs, as a result of the
Slide 17: Faes Farma - Caring for tomorrow, today
cl FAES FARMA Caring for tomorrow, today
Slide 18: Disclaimer
DISCLAIMER This presentation has been prepared and published by Faes Farma Group and is presented for informational purposes only. This presentation is not a brochure, nor is it an offer or recommendation to make an investment. This presentation does not imply any subscription commitment, nor an off